Profile data is unavailable for this security.
About the company
Therma Bright Inc. is a Canada-based developer and investment partner specializing in advanced diagnostic and medical device technologies that address key healthcare challenges. The Company is developing, acquiring, manufacturing and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace focused on three key strategic areas: respiratory disease, vascular health and consumer medical devices. Its respiratory disease portfolio includes AI4LYF Digital Cough Technology and InStatin-novel inhaled treatment for asthma and COPD. Its vascular disease portfolio includes Inretio-ischemic stroke treatment and Venowave-Deep Vein Thrombosis Treatment Device (DVT). Its consumer health portfolio consists of AcuVid Covid-19 Rapid Antigen Saliva Test, Benepod-Contrast Therapy Device, TheroZAP-Thermal Therapy Device and InterceptCS-Cold Sore Prevention System. The Company holds trademarks for Therozap, InterceptCS and AcuVid.
- Revenue in CAD (TTM)75.23k
- Net income in CAD-4.16m
- Incorporated2018
- Employees--
- LocationTherma Bright Inc345 Danforth AvenueTORONTO M4K 1N7CanadaCAN
- Phone+1 (416) 867-2353
- Fax+1 (416) 867-4566
- Websitehttps://thermabright.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EvokAI Creative Labs Inc | -13.05k | -13.68m | 874.63k | -- | -- | -- | -- | -- | -1.94 | -1.94 | -0.0018 | -0.1761 | -0.0019 | -- | -- | -- | -194.40 | -1,742.96 | -206.27 | -3,585.36 | -- | -- | -- | -- | -- | -69.67 | -- | -- | -- | -- | -3,392.77 | -- | -- | -- |
| CardioComm Solutions Inc | 386.53k | -404.82k | 1.98m | 16.00 | -- | -- | -- | 5.11 | -0.0021 | -0.0021 | 0.002 | -0.0029 | 1.31 | 1.48 | 2.97 | -- | -137.51 | -20.56 | -- | -- | 87.25 | 83.20 | -104.73 | -9.13 | 0.2344 | -11.99 | 8.47 | -- | -39.90 | -9.65 | -99.92 | -- | -10.07 | -- |
| Therma Bright Inc | 75.23k | -4.16m | 3.41m | -- | -- | -- | -- | 45.31 | -0.0729 | -0.0729 | 0.0013 | -0.0248 | 0.0406 | 0.1726 | 0.3653 | -- | -224.22 | -203.01 | -69,250.66 | -507.57 | 65.25 | -- | -5,523.12 | -9,158.61 | 0.1182 | -0.6815 | -- | -- | 207.90 | 84.25 | -77.17 | -- | -- | -- |
| Zero Candida Technologies Inc | -100.00bn | -100.00bn | 3.43m | -- | -- | 2.09 | -- | -- | -- | -- | -- | 0.0839 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0174 | -- | -- | -- | -- | -- | -- | -- |
| Kovo+Holdings Inc | 14.83m | -8.71m | 5.31m | -- | -- | -- | -- | 0.3579 | -0.0544 | -0.0544 | 0.0928 | -0.0584 | 0.8026 | -- | 33.43 | -- | -47.17 | -- | -- | -- | -- | -- | -58.77 | -- | -- | -0.798 | 1.60 | -- | 5.45 | -- | -25.26 | -- | -- | -- |
| NuGen Medical Devices Inc | 589.43k | -2.12m | 6.81m | 12.00 | -- | -- | -- | 11.56 | -0.0092 | -0.0092 | 0.0026 | -0.0381 | 0.0461 | 0.7839 | 19.59 | -- | -16.58 | -- | -20.05 | -- | 54.97 | -- | -359.36 | -- | 3.90 | -- | 1.90 | -- | 204.73 | -- | 44.18 | -- | -- | -- |
